We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
-4.61%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$4.5B
AUM Growth
-$546M
Cap. Flow
-$309M
Cap. Flow %
-6.85%
Top 10 Hldgs %
82.03%
Holding
109
New
17
Increased
29
Reduced
12
Closed
18

Top Buys

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$24.5M
2
ATH
Athene Holding Ltd. Class A Common Shares
ATH
+$18.5M
3
AGIO icon
Agios Pharmaceuticals
AGIO
+$18.4M
4
ZTO icon
ZTO Express
ZTO
+$14.4M
5
CELG
Celgene Corp
CELG
+$11.1M

Top Sells

Rank Stock Value
1
GS icon
Goldman Sachs
GS
+$32.3M
2
BAC icon
Bank of America
BAC
+$19.3M
3
ARRY
Array Biopharma Inc
ARRY
+$16.6M
4
MS icon
Morgan Stanley
MS
+$13.2M
5
APTV icon
Aptiv
APTV
+$10.7M

Sector Composition

Rank Sector Weight
1 Consumer Staples 46.77%
2 Healthcare 25.98%
3 Consumer Discretionary 7.97%
4 Financials 0.43%
5 Industrials 0.27%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CLVS
76
DELISTED
Clovis Oncology, Inc.
CLVS
$2.22M 0.05%
+50,000
New +$1.76M
NVLN
77
DELISTED
Novelion Therapeutics Inc. Common Shares
NVLN
$2.16M 0.05%
+256,400
New +$2.27M
AGEN
78
CALL
Agenus
AGEN
$280M
$2.06M 0.05%
25,475
– –
JUNO
79
CALL
DELISTED
Juno Therapeutics, Inc.
JUNO
$1.89M 0.04%
100,000
– –
MDCO
80
DELISTED
Medicines Co
MDCO
$1.7M 0.04%
+50,000
New +$1.77M
AIMT
81
DELISTED
Aimmune Therapeutics
AIMT
$1.67M 0.04%
+81,600
New +$1.67M
LRMR icon
82
Larimar Therapeutics
LRMR
$381M
$1.59M 0.04%
+41,667
New +$1.69M
IBRX icon
83
ImmunityBio
IBRX
$7.16B
$1.29M 0.03%
225,000
– –
ADAP
84
DELISTED
Adaptimmune Therapeutics
ADAP
$1.22M 0.03%
300,000
+100,000
+50% +$480K
KDNY
85
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$1.14M 0.03%
20,000
– –
DMTX
86
DELISTED
Dimension Therapeutics, Inc
DMTX
$1.02M 0.02%
234,493
– –
AKAO
87
DELISTED
Achaogen Inc
AKAO
$781K 0.02%
+60,000
New +$412K
NVAX icon
88
Novavax
NVAX
$1.21B
$630K 0.01%
25,000
– –
CEMP
89
DELISTED
Cempra, Inc.
CEMP
$560K 0.01%
200,000
– –
IMDX
90
Insight Molecular Diagnostics
IMDX
$144M
$452K 0.01%
3,205
– –
CLCD
91
DELISTED
CoLucid Pharmaceuticals, Inc.
CLCD
$203K ﹤0.01%
5,575
-50,000
-90% -$1.77M
APTV icon
92
Aptiv
APTV
$12.4B
– –
-150,000
Closed -$10.7M
BAC icon
93
Bank of America
BAC
$434B
– –
-1,000,000
Closed -$19.3M
GOOGL icon
94
CALL
Alphabet (Google) Class A
GOOGL
$4.12T
– –
-800,000
Closed -$32.2M
GS icon
95
CALL
Goldman Sachs
GS
$294B
– –
-2,750,000
Closed -$443M
GS icon
96
Goldman Sachs
GS
$294B
– –
-200,000
Closed -$32.3M
MET icon
97
MetLife
MET
$62.6B
– –
-196,350
Closed -$9.01M
MS icon
98
Morgan Stanley
MS
$324B
– –
-350,000
Closed -$13.2M
NTB icon
99
Bank of N.T. Butterfield & Son
NTB
$2.43B
– –
-200,000
Closed -$4.95M
RARE icon
100
CALL
Ultragenyx Pharmaceutical
RARE
$2.49B
– –
-50,000
Closed -$3.55M
1 2 3
4
5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q4 2016 Portfolio in Review

As of Q4 2016, Artal Group held 109 positions worth $4.5B, down 11% from $5.05B the previous quarter. Its ten largest holdings account for 82% of the portfolio.

Artal Group withdrew a net $309M in Q4 2016, closing 18 positions and reducing 12 holdings. Its most notable exit was Goldman Sachs, an estimated $32.3M position sold in full.

By sector, the portfolio is most concentrated in Consumer Staples at 47% of assets, up from 41% a quarter earlier, followed by Healthcare and Consumer Discretionary.

Against the trend, Artal Group opened a new position in Alexion Pharmaceuticals worth $24.5M.

  • Artal Group's largest Q4 2016 buy was Alexion Pharmaceuticals: 200,000 shares worth $24.5M.
  • Artal Group added most to Agios Pharmaceuticals in Q4 2016, an estimated $18.4M increase.
  • Artal Group's biggest Q4 2016 reduction was Array Biopharma Inc, cutting an estimated $16.6M.
  • Artal Group fully exited Goldman Sachs in Q4 2016, selling an estimated $32.3M.
  • Artal Group's ten largest holdings make up 82% of its $4.5B portfolio in Q4 2016.
  • Artal Group opened 17 new positions and closed 18 in Q4 2016.
  • Artal Group's portfolio value fell 11% quarter-over-quarter to $4.5B.

Based on Artal Group's 13F filing for Q4 2016, filed 14 Feb 2017.